ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 267 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2020. The put-call ratio across all filers is 0.63 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $594 | -24.6% | 22,100 | 0.0% | 0.02% | -28.6% |
Q2 2023 | $788 | +61.5% | 22,100 | +15.1% | 0.04% | +40.0% |
Q1 2023 | $488 | -27.5% | 19,200 | +15.7% | 0.02% | -30.6% |
Q4 2022 | $673 | -99.9% | 16,600 | 0.0% | 0.04% | +20.0% |
Q3 2022 | $549,000 | -6.0% | 16,600 | 0.0% | 0.03% | +7.1% |
Q2 2022 | $584,000 | -41.0% | 16,600 | -22.8% | 0.03% | -24.3% |
Q1 2022 | $989,000 | -30.6% | 21,500 | 0.0% | 0.04% | -22.9% |
Q4 2021 | $1,425,000 | +6.2% | 21,500 | 0.0% | 0.05% | +2.1% |
Q3 2021 | $1,342,000 | -24.6% | 21,500 | 0.0% | 0.05% | -23.0% |
Q2 2021 | $1,781,000 | +50.0% | 21,500 | +20.1% | 0.06% | +29.8% |
Q1 2021 | $1,187,000 | -13.5% | 17,900 | 0.0% | 0.05% | -19.0% |
Q4 2020 | $1,373,000 | +52.6% | 17,900 | -14.4% | 0.06% | +38.1% |
Q3 2020 | $900,000 | -12.5% | 20,900 | -12.2% | 0.04% | -14.3% |
Q2 2020 | $1,028,000 | +50.1% | 23,800 | 0.0% | 0.05% | +19.5% |
Q1 2020 | $685,000 | -37.6% | 23,800 | +37.6% | 0.04% | -10.9% |
Q4 2019 | $1,097,000 | – | 17,300 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
WESTERN FINANCIAL Corp | 820,303 | $54,386,000 | 28.54% |
JOHNSON & JOHNSON | 3,260,869 | $216,196,000 | 24.61% |
ACT CAPITAL MANAGEMENT, LLC | 210,500 | $13,956,000 | 10.09% |
Aquilo Capital Management, LLC | 700,426 | $46,438,000 | 5.27% |
WEALTH EFFECTS LLC | 145,960 | $9,677,000 | 4.02% |
Evolutionary Tree Capital Management, LLC | 115,580 | $7,663,000 | 3.68% |
ACUTA CAPITAL PARTNERS, LLC | 105,500 | $6,995,000 | 2.94% |
Privium Fund Management B.V. | 204,393 | $13,766,000 | 2.73% |
L1 Capital Pty Ltd | 292,735 | $19,408,000 | 2.24% |
Avidity Partners Management LP | 875,000 | $58,013,000 | 1.23% |